Know Cancer

or
forgot password

Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Study Evaluating Quality of Life in Patients With Advanced Malignant Tumors With or Without "add-on" Homeopathy


Phase 2/Phase 3
18 Years
N/A
Open (Enrolling)
Both
Malignant Tumors

Thank you

Trial Information

Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Study Evaluating Quality of Life in Patients With Advanced Malignant Tumors With or Without "add-on" Homeopathy


The EORTC-QLQ-C30 as well as a VAS scale for subjective well-being will be filled out by the
patients.


Inclusion Criteria:



- Informed consent

- Clinical diagnosis of advanced tumor stages of glioblastoma IV, metastasized sarcoma,
as well as non small-cell lung carcinoma (NSCLC) IV.

Exclusion Criteria:

- Pregnant patients

Type of Study:

Interventional

Study Design:

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Supportive Care

Outcome Measure:

Life quality

Outcome Description:

Life quaity is evaluated by using the results of the EORTC-QLQ-C30 questionnaire

Outcome Time Frame:

7 years

Safety Issue:

No

Principal Investigator

Michael Frass, Prof. Dr.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Medical University Vienna

Authority:

Austria: Agency for Health and Food Safety

Study ID:

5

NCT ID:

NCT01509612

Start Date:

January 2011

Completion Date:

January 2019

Related Keywords:

  • Malignant Tumors
  • cancer
  • additive homeopathy
  • patients with advanced malignant tumors
  • Neoplasms

Name

Location